Search | Clinical Trials Finder

Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP), EPP2
Interventions: PORT-77, Placebo; Drug
Lead sponsor: Portal Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Huntington Beach, California • Cincinnati, Ohio

Conditions: Binocular Dysfunction, Vertical Heterophoria, Vision, Binocular, Vision Disparity
Interventions: Lenses containing prismatic correction, Lenses not containing prismatic correction; Device
Lead sponsor: Vision Specialists of Birmingham; Other
Eligibility: 14 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Birmingham, Michigan

Conditions: Lyme Disease
Interventions: VLA15, Normal Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 3,547 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 65
States / cities: Birmingham, Alabama • Guntersville, Alabama • Bellflower, California + 55 more

Conditions: Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
Interventions: BFKB8488A, Placebo; Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Anniston, Alabama • Coronado, California • Stanford, California + 12 more

Conditions: Combat Related Symptoms, Irritability, Anger
Interventions: cranial electrotherapy stimulation (CES) with Alpha-Stim, placebo; Procedure
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Fort Hood, Texas • Fort Sam Houston, Texas

Conditions: Refractory Chronic Cough
Interventions: Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG, Amitriptyline 50 MG, Placebo 30 MG, Placebo 60 MG; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HSV
Interventions: Benzoyl Peroxide 10% Bar, Placebo; Drug · Other
Lead sponsor: Greg Bew; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evans, Georgia

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel; Biological · Other · Drug
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more

Conditions: Post-stroke Shoulder Pain, Hemiplegic Shoulder Pain
Interventions: Smartpatch Peripheral Nerve Stimulation (PNS) System; Device
Lead sponsor: SPR Therapeutics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Chicago, Illinois • West Orange, New Jersey • New York, New York + 2 more

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Generalized Tonic Clonic Seizures
Interventions: Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more

Conditions: Chronic Pain, Opioid Pain Medication
Interventions: Buprenorphine Initiation - Phase I, Gabapentin + Buprenorphine - Phase II, Placebo + Buprenorphine - Phase II, Buprenorphine taper - Phase II; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Epilepsy, Dravet Syndrome
Interventions: GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 4 Years to 10 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Constipation, Cancer, Functional Constipation
Interventions: MZRW; Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Knee Osteoarthritis
Interventions: canakinumab, LNA043, Placebo to canakinumab; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Budesonide / Formoterol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more

Conditions: Pain Management
Interventions: Transcutaneous Electrical Nerve Stimulation (TENS); Device
Lead sponsor: Jennifer E. Lee; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Ulcerative Colitis (UC)
Interventions: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Chula Vista, California • La Jolla, California • Lancaster, California + 34 more

Conditions: Pneumonia, Bacterial
Interventions: CAL02, Placebo; Drug
Lead sponsor: Eagle Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more

Conditions: Alcoholic Hepatitis
Interventions: Fecal Microbiota Transplantation, Placebo; Biological · Other
Lead sponsor: Prasun Kumar Jalal; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Placebo, Maralixibat, Volixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Peripheral Arterial Disease, Peripheral Artery Disease
Interventions: Placebo, Beet root juice; Dietary Supplement
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lower Respiratory Tract Infection
Interventions: Azithromycin, Placebo, VIDAS B.R.A.H.M.S Procalcitonin Test (PCT); Drug · Other · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Durham, North Carolina + 1 more

Search by objective public record fields.

A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

Cranial Electrotherapy Stimulation (CES) for Soldiers With Combat-Related Symptoms

Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough

Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

A Study of Herbal Supplements in Cancer Survivors With Constipation

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

TENS for Testicular Pain (ICO): A Randomized Controlled Trial

Efficacy & Safety of TD-1473 in Ulcerative Colitis

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

Dietary Nitrate Supplementation and Thermoregulation

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level